• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初始抗生素治疗失败的影响:医疗保健相关性或医院获得性肺炎的真实世界观察。

The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia.

机构信息

AstraZeneca, Health Economics and Outcomes Research, Gaithersburg, MD, USA.

IQVIA, Real-World Insights, Saint-Ouen, France.

出版信息

J Infect. 2018 Jul;77(1):9-17. doi: 10.1016/j.jinf.2018.04.002. Epub 2018 May 6.

DOI:10.1016/j.jinf.2018.04.002
PMID:29742471
Abstract

OBJECTIVES

To assess real-world treatment patterns and clinical outcomes associated with initial antibiotic therapy (IAT, antibiotics received ≤ 48 h post-initiation of antibiotic therapy), including level of IAT failure, and potential risk factors for IAT failure in healthcare-associated infections.

METHODS

Data were obtained from medical records of adult patients hospitalized with healthcare-associated pneumonia (HCAP) and nosocomial pneumonia (NP), including ventilator-associated pneumonia, from 1 July 2013 to 30 June 2014 in Brazil, France, Italy, Russia and Spain during the retrospective, observational study, RECOMMEND (NCT02364284; D4280R00005). Potential risk factors for IAT failure were explored using logistic regression analyses.

RESULTS

Mean (standard deviation) age and Deyo-Charlson Comorbidity Score were 66.0 (16.2) years and 2.4 (2.4), respectively (N = 451). Most patients (62.5%) received monotherapy. Mean (standard deviation) duration of IAT was 8.8 (7.2) days. Multidrug-resistant (MDR) pathogens were identified in 52.4% of patients with ≥ 1 pathogen isolated (154/294). IAT failure was recorded in 72.5% of patients and was significantly associated with isolation of a MDR pathogen and country using multivariate analyses.

CONCLUSIONS

Real-world data demonstrate the burden of HCAP/NP, with high rates of IAT failure. The association of IAT failure with MDR pathogens highlights the urgent need to understand and account for local prevalence of MDR pathogens when selecting IAT for the management of HCAP/NP.

摘要

目的

评估与初始抗生素治疗(IAT,抗生素治疗开始后≤48 小时内接受的抗生素)相关的真实世界治疗模式和临床结局,包括 IAT 失败率,以及医疗保健相关性感染中 IAT 失败的潜在危险因素。

方法

数据来自 2013 年 7 月 1 日至 2014 年 6 月 30 日期间在巴西、法国、意大利、俄罗斯和西班牙进行的回顾性观察性研究 RECOMMEND(NCT02364284;D4280R00005)中因医疗保健相关性肺炎(HCAP)和医院获得性肺炎(NP)住院的成年患者的病历,包括呼吸机相关性肺炎。使用逻辑回归分析探讨 IAT 失败的潜在危险因素。

结果

平均(标准差)年龄和 Deyo-Charlson 合并症评分分别为 66.0(16.2)岁和 2.4(2.4)(N=451)。大多数患者(62.5%)接受单药治疗。IAT 的平均(标准差)持续时间为 8.8(7.2)天。≥1 种病原体分离的患者中,有 52.4%(154/294)发现了耐多药病原体。在多变量分析中,72.5%的患者记录了 IAT 失败,与分离出耐多药病原体和国家显著相关。

结论

真实世界数据表明 HCAP/NP 的负担沉重,IAT 失败率很高。IAT 失败与耐多药病原体的关联突出表明,在选择 IAT 治疗 HCAP/NP 时,迫切需要了解和考虑当地耐多药病原体的流行情况。

相似文献

1
The impact of initial antibiotic treatment failure: Real-world insights in healthcare-associated or nosocomial pneumonia.初始抗生素治疗失败的影响:医疗保健相关性或医院获得性肺炎的真实世界观察。
J Infect. 2018 Jul;77(1):9-17. doi: 10.1016/j.jinf.2018.04.002. Epub 2018 May 6.
2
The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection.初始抗生素治疗失败的影响:复杂性尿路感染患者的真实世界观察。
J Infect. 2018 Feb;76(2):121-131. doi: 10.1016/j.jinf.2017.11.001. Epub 2017 Nov 8.
3
Healthcare-Associated Pneumonia and Hospital-Acquired Pneumonia: Bacterial Aetiology, Antibiotic Resistance and Treatment Outcomes: A Study From North India.医疗相关性肺炎和医院获得性肺炎:细菌病因、抗生素耐药性和治疗结果:来自印度北部的一项研究。
Lung. 2018 Aug;196(4):469-479. doi: 10.1007/s00408-018-0117-7. Epub 2018 Apr 25.
4
The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection.初始抗生素治疗失败的影响:对复杂性医疗保健相关腹腔内感染患者的真实世界见解
Infect Drug Resist. 2019 Jan 31;12:329-343. doi: 10.2147/IDR.S184116. eCollection 2019.
5
Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.抗生素使用时长对铜绿假单胞菌呼吸机相关性肺炎患者临床事件的影响:一项随机对照研究的研究方案
Trials. 2017 Jan 23;18(1):37. doi: 10.1186/s13063-017-1780-3.
6
A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.一种新的医疗相关性肺炎策略:一项使用多重耐药病原体危险因素选择初始经验性治疗的 2 年前瞻性多中心队列研究。
Clin Infect Dis. 2013 Nov;57(10):1373-83. doi: 10.1093/cid/cit571. Epub 2013 Sep 2.
7
Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.诗里拉吉医院成人医院获得性肺炎和呼吸机相关性肺炎:病因、临床结局及抗菌药物耐药性的影响
J Med Assoc Thai. 2010 Jan;93 Suppl 1:S126-38.
8
Reinventing the wheel: Impact of prolonged antibiotic exposure on multidrug-resistant ventilator-associated pneumonia in trauma patients.重新发明轮子:抗生素暴露时间延长对创伤患者多重耐药呼吸机相关性肺炎的影响。
J Trauma Acute Care Surg. 2018 Aug;85(2):256-262. doi: 10.1097/TA.0000000000001936.
9
An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.多重耐药革兰阴性菌导致的医院获得性肺炎和呼吸机相关性肺炎管理指南概述。
Curr Opin Infect Dis. 2019 Dec;32(6):656-662. doi: 10.1097/QCO.0000000000000596.
10
Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review.治疗革兰氏阴性菌引起的医院获得性肺炎的抗生素肺部药代动力学:系统评价。
Int J Antimicrob Agents. 2019 Mar;53(3):234-245. doi: 10.1016/j.ijantimicag.2018.11.011. Epub 2018 Nov 23.

引用本文的文献

1
Promoting real-world evidence use for antimicrobial stewardship in Latin America: evaluation of impact of a two-part educational webinar series.促进拉丁美洲抗菌药物管理中真实世界证据的应用:两部分组成的教育网络研讨会系列的影响评估
JAC Antimicrob Resist. 2025 Apr 18;7(2):dlaf056. doi: 10.1093/jacamr/dlaf056. eCollection 2025 Apr.
2
Optimizing patient outcomes in severe pneumonia: the role of multiplex PCR in the treatment of critically ill patients.优化重症肺炎患者的治疗结局:多重聚合酶链反应在危重症患者治疗中的作用
Front Med (Lausanne). 2024 Aug 21;11:1391641. doi: 10.3389/fmed.2024.1391641. eCollection 2024.
3
New Agents Are Coming, and So Is the Resistance.
新的病原体正在出现,耐药性问题也随之而来。
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.
4
Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review.医院获得性肺炎需更新的十个问题:专家综述
J Clin Med. 2023 Oct 14;12(20):6526. doi: 10.3390/jcm12206526.
5
Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.在随机、对照的 3 期 ASPECT-NP 试验中,在纳入头孢他洛滨/他唑巴坦与美罗培南比较的随机、对照 3 期 ASPECT-NP 试验之前,对于初始抗菌治疗失败的医院获得性/呼吸机相关性细菌性肺炎参与者的结局。
Crit Care. 2022 Dec 1;26(1):373. doi: 10.1186/s13054-022-04192-w.
6
Update on the Management of Surgical Site Infections.手术部位感染管理的最新进展
Antibiotics (Basel). 2022 Nov 11;11(11):1608. doi: 10.3390/antibiotics11111608.
7
Early appropriate diagnostics and treatment of MDR Gram-negative infections.多重耐药革兰氏阴性菌感染的早期适当诊断与治疗。
JAC Antimicrob Resist. 2022 Sep 13;4(5):dlac089. doi: 10.1093/jacamr/dlac089. eCollection 2022 Oct.
8
Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in mice.免疫抑制在小鼠鲍曼不动杆菌肺炎中拓宽了耐药性和治疗失败的进化途径。
Nat Microbiol. 2022 Jun;7(6):796-809. doi: 10.1038/s41564-022-01126-8. Epub 2022 May 26.
9
Diagnosis of Multidrug-Resistant Pathogens of Pneumonia.耐多药肺炎病原体的诊断
Diagnostics (Basel). 2021 Dec 7;11(12):2287. doi: 10.3390/diagnostics11122287.
10
Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis.脓毒症新型抗感染治疗选择与优化药物方案的综述
Front Med (Lausanne). 2021 Apr 15;8:640740. doi: 10.3389/fmed.2021.640740. eCollection 2021.